ABNOM
☆ I dtorthaí 2022 Stiftung Warentest ón nGearmáin, ní raibh sástacht na dtomhaltóirí le ModelDerm ach beagán níos ísle ná mar a bhí le comhairliúchán teileamhíochaine íoctha.
References
Is eol don léasair Q-switched Nd:YAG cóireáil éifeachtach a dhéanamh ar nevus Ota agus coinníollacha comhchosúla. Rinneamar staidéar féachaint cé chomh maith agus a d'oibrigh léasair high-fluence 1064 nm Q-switched Nd:YAG ar spotaí Mongóilis i limistéir neamhghnácha, gan an craiceann a dhéanamh níos éadrom. Rinneamar staidéar ar 61 othar leis na spotaí seo, ag scrúdú 70 loit san iomlán. Cóireáladh leath de na loit leis an léasair, agus fágadh cuid eile gan chóireáil le haghaidh comparáide. Rinneamar measúnú ar na torthaí ag baint úsáide as scála agus gléas ar a dtugtar Mexameter® chun leibhéil melanin a thomhas. Rinneadh obair leantach ar othair ar feadh 14 mhí ar an meán sa ghrúpa cóireála agus 18 mí sa ghrúpa breathnóireachta. Ag deireadh an staidéir, fuaireamar difríochtaí suntasacha sna scóir scála agus leibhéil melanin idir na grúpaí cóireáilte agus neamhchóireáilte, agus léirigh an grúpa cóireáilte léasair torthaí níos fearr. Bhí an léasair high-fluence Q-switched Nd:YAG , gan éadromú craicinn ina chúis, éifeachtach agus sábháilte chun na spotaí neamhghnácha Mongóilis seo a chóireáil.
The Q-switched Nd:YAG laser is known to effectively treat nevus of Ota and similar conditions. We conducted a study to see how well a high-fluence 1064 nm Q-switched Nd:YAG laser worked on Mongolian spots in unusual areas, without causing the skin to lighten. We studied 61 patients with these spots, examining a total of 70 lesions. Half of lesions were treated with the laser, while others were left untreated for comparison. We evaluated the results using a scale and a device called a Mexameter® to measure melanin levels. Patients were followed up for an average of 14 months in the treatment group and 18 months in the observation group. At the end of the study, we found significant differences in the scale scores and melanin levels between the treated and untreated groups, with the laser-treated group showing better outcomes. The high-fluence Q-switched Nd:YAG laser, without causing skin lightening, proved effective and safe for treating these unusual Mongolian spots.
The Q-switched Nd:YAG laser is known to effectively treat nevus of Ota and similar conditions. We conducted a study to see how well a high-fluence 1064 nm Q-switched Nd:YAG laser worked on Mongolian spots in unusual areas, without causing the skin to lighten. We studied 61 patients with these spots, examining a total of 70 lesions. Half of lesions were treated with the laser, while others were left untreated for comparison. We evaluated the results using a scale and a device called a Mexameter® to measure melanin levels. Patients were followed up for an average of 14 months in the treatment group and 18 months in the observation group. At the end of the study, we found significant differences in the scale scores and melanin levels between the treated and untreated groups, with the laser-treated group showing better outcomes. The high-fluence Q-switched Nd:YAG laser, without causing skin lightening, proved effective and safe for treating these unusual Mongolian spots.
Rinneamar staidéar ar éifeachtacht agus ar shábháilteacht úsáid a bhaint as cóireáil léasair ar leith do ABNOM , agus d'fhéachamar ar na fachtóirí a d'fhéadfadh tionchar a bheith acu ar chomh maith agus a oibríonn sé. D'fhéachamar ar 110 othar a raibh ABNOM acu agus a fuair idir dhá agus naoi gcóireáil léasair. Fuaireamar amach gur oibrigh an chóireáil níos fearr dá fhaide a rinneadh í, ach ní raibh sé chomh maith in othair níos sine. D'oibrigh sé níos fearr freisin in othair le craiceann níos éadroime (cineál III) agus limistéir níos lú (níos lú ná 10 cm2) . Le melasma mar aon le ABNOM ní raibh an chóireáil chomh héifeachtach céanna. Ní raibh an chuma ar an scéal go ndearna dath nó líon na gceantar a raibh tionchar orthu difríocht. Fuair thart ar 10% d'othair spotaí níos dorcha tar éis cóireála. Thug cóireáil luath iolrach torthaí maithe. Is dóichí go bhfaighidh othair níos sine le craiceann níos dorcha agus spotaí níos dorcha spotaí níos dorcha tar éis cóireála. I gcás othair a bhfuil ABNOM agus melasma acu, is fearr léasair ísealfhuinnimh a úsáid chun an melasma a dhéanamh níos measa a sheachaint.
To evaluate the efficacy and safety of 1064-nm Q-switched Nd:YAG laser (QSNYL) therapy for ABNOM and to identify the factors influencing the outcome. A total of 110 patients with ABNOM were retrospectively evaluated and received two-to-nine treatment sessions. The curative effect was positively correlated with the treatment time and negatively correlated with the increasing age at first treatment (p < 0.05). The curative effect was better in patients with skin type III than those with type IV ( p < 0.05) and in patients with a lesion area of less than 10 cm2 than those with a larger affected area (p < 0.05). Additionally, the treatment effect was poorer in patients with concomitant melasma (p < 0.05). The treatment effect was not significantly correlated with the lesion color or number of affected sites (p > 0.05). Eleven patients (10%) developed postinflammatory hyperpigmentation (PIH). Early and repeated QSNYL therapy achieved satisfactory results for ABNOM. The risk of PIH after laser treatment is highest among patients with older age, darker lesion color, and darker skin color. For patients with ABNOM with concurrent melasma, low-energy laser therapy is recommended to reduce the risk of melasma aggravation.
To evaluate the efficacy and safety of 1064-nm Q-switched Nd:YAG laser (QSNYL) therapy for ABNOM and to identify the factors influencing the outcome. A total of 110 patients with ABNOM were retrospectively evaluated and received two-to-nine treatment sessions. The curative effect was positively correlated with the treatment time and negatively correlated with the increasing age at first treatment (p < 0.05). The curative effect was better in patients with skin type III than those with type IV ( p < 0.05) and in patients with a lesion area of less than 10 cm2 than those with a larger affected area (p < 0.05). Additionally, the treatment effect was poorer in patients with concomitant melasma (p < 0.05). The treatment effect was not significantly correlated with the lesion color or number of affected sites (p > 0.05). Eleven patients (10%) developed postinflammatory hyperpigmentation (PIH). Early and repeated QSNYL therapy achieved satisfactory results for ABNOM. The risk of PIH after laser treatment is highest among patients with older age, darker lesion color, and darker skin color. For patients with ABNOM with concurrent melasma, low-energy laser therapy is recommended to reduce the risk of melasma aggravation.
○ Cóireáil
Is annamh a chabhraíonn gníomhairí whitening. Murab ionann agus melasma, is féidir ABNOM a fheabhsú le cóireáil léasair agus fágtar é a bhaint gan atarlú. Is féidir cóireáil léasair a dhéanamh 10 go 20 uair chun cóireáil ABNOM.
#QS1064 laser